Zdrowie i gospodarka · 27/07/2018

FDA Announces Draft Guidance for Rare Diseases with Substrate Deposition

The FDA is releasing a draft guidance document to help pharmaceutical companies demonstrate the effectiveness of new treatments for slowly progressive, low-prevalence rare diseases caused by single enzyme defects, which often involve substrate deposition.